Daewoong Pharmaceutical Unveils Comprehensive Data on 104 IPF Patients at ERS 2026 Conference#South_Korea#Seoul#Daewoong#Bersiporocin#IPF_Drug
Daewoong Pharmaceutical Unveils Comprehensive Data on 104 IPF Patients at ERS 2026 Conference
At the ERS 2026, Daewoong presented detailed data on 104 patients from their Phase 2 trial for the IPF drug candidate Bersiporocin. This study brings insights into patients' response to treatment.
third-news.com
September 24, 2026 at 7:49 AM
Daewoong Pharmaceutical Unveils Comprehensive Data on 104 IPF Patients at ERS 2026 Conference#South_Korea#Seoul#Daewoong#Bersiporocin#IPF_Drug